Professor Michael J. Tisdale

Professor of Cancer Biochemistry

Member of the Pharmacy and Biology Teaching Programmes

School of Life & Health Sciences
Aston University
Aston Triangle
Birmingham
B4 7ET
UK

email: [email protected]
telephone: +44 (0) 121 204 4021
fax: +44 (0) 121 204 3743

Research Theme

Chronic and Communicable Conditions

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA)

I joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980. Prior to that I spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research.

BSc (lst Class Honours) (Chemistry), Hull, 1967
PhD (Chemistry), London, 1970
DSc (Cancer Biochemistry), London, 1983

• 1989–date: Professor of Cancer Biochemistry, Aston University
• 1992-95: Head of Department, Pharmaceutical and Biological Sciences, Aston University
• 1984-89: Reader, Department of Pharmaceutical Sciences, Aston University
• 1981-84: Senior Research Fellow, CRC Experimental Chemotherapy Group, Aston University
• 1972-81: Lecturer Department of Biochemistry, St Thomas’s Medical School
• 1971-72: Scientific Officer, Rothamstead Experimental Station
• 1970-71: MRC Fellow, Institute of Cancer Research

Mainly related to cancer causation, biology treatment and associated conditions e.g. cachexia.

Modules: PH3 CM1, PH1 CM1, BY3 CM1, BY1 CM1, BY2 BD1, PH3 MC1

Cancer cachexia, mechanism and treatment. Treatment of obesity and type 2 diabetes.

Specifically:

• Signal transduction pathways involved in muscle catabolism by proteolysis-inducing factor (PIF)
• Cloning and sequencing of cellular receptor for PIF
• Cloning and expression of PIF
• Investigation of antibodies to the PIF receptor as anticachectic agents
• Action of eicosapentaenoic acid (EPA) in preventing muscle catabolism by PIF
• Role of EPA in attenuating muscle catabolism in catabolic states other than cancer cachexia
• Clinical evaluation of EPA in the treatment of cancer cachexia

*Awarding Body*	*Title of Project*	*Amount (£)*	*Dates*
Halsa Pharmaceuticals	Evaluation of zinc-alpha 2-glycoprotein for the treatment of obesity	220,000	2008-2010
Bioneris	Anticachectic activity of a novel agent	135,000	2006-2009
Ross Products Division	Effect of ingredients in an animal model of cachexia	490,536	2002-2008
British Technology Group	Studies on the PIF receptor	74,986	2005
Novartis Medical Nutrition	Investigation into the mechanism for depression of protein synthesis in cancer	152,404	2004-2007

Ark Therapeutics	To determine whether angiotensin II has a direct effect on muscle protein degradation	142, 528	2003-2005
Bayer Healthcare	The potential therapeutic use of zinc-alpha2-glcyoprotein for obesity and type II diabetes	196,868	2002-2004
Lustgarten Foundation	Cloning and expression of a muscle receptor for a cancer-cachectic factor	50,655	2003
Novartis Consumer Health	Studies on cancer cachexia	131,964	2003-2004

Recent Publications

Skipworth, RJE, Stephens, NA, Johns, N, Guttridge, DC, Tisdale, MJ, Baracos, VE & Glass, DJ 2016, 'Ken Fearon: obituary' Cell metabolism, vol. 24, no. 6, pp. 765-766. DOI:10.1016/j.cmet.2016.11.010
Mirza, KA, Luo, M, Pereira, S, Voss, A, Das, T & Tisdale, MJ 2016, 'In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C₂C₁₂myotubes' In Vitro Cellular and Developmental Biology: Animal, vol. 52, no. 8, pp. 838–845. DOI:10.1007/s11626-016-0051-z
Mirza, KA, Pereira, SL, Edens, NK & Tisdale, MJ 2014, 'Attenuation of muscle wasting in murine C₂C₁₂myotubes by epigallocatechin-3-gallate' Journal of Cachexia, Sarcopenia and Muscle, vol. 5, no. 4, pp. 339-345. DOI:10.1007/s13539-014-0139-9
Mirza, KA & Tisdale, MJ 2014, 'Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle' British Journal of Cancer, vol. 111, no. 5, pp. 903-908. DOI:10.1038/bjc.2014.379
Mirza, KA, Pereira, SL, Voss, AC & Tisdale, MJ 2014, 'Comparison of the anticatabolic effects of leucine and Ca-ß-hydroxy-ß-methylbutyrate in experimental models of cancer cachexia' Nutrition, vol. 30, no. 7-8, pp. 807-813. DOI:10.1016/j.nut.2013.11.012
Russell, ST & Tisdale, MJ 2012, 'Role of ß-adrenergic receptors in the oral activity of zinc-a2-glycoprotein (ZAG)' Endocrinology, vol. 153, no. 10, pp. 4696-4704. DOI:10.1210/en.2012-1260
Russell, ST & Tisdale, MJ 2012, 'Role of ß-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-a2-glycoprotien (ZAG)' BBA - Molecular and Cell Biology of Lipids, vol. 1821, no. 4, pp. 590-599. DOI:10.1016/j.bbalip.2011.12.003
Mirza, K & Tisdale, M 2011, 'Role of Ca²⁺in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle' Cellular Signalling, vol. 24, no. 11, pp. 2118–2122. DOI:10.1016/j.cellsig.2012.07.016
Tisdale, M 2011, 'Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle' Journal of Cachexia, Sarcopenia and Muscle, vol. 2, no. 3, PMC3177039, pp. 181–188. DOI:10.1007/s13539-011-0037-3
Mirza, K, Wyke, SM & Tisdale, M 2011, 'Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF)' British Journal of Cancer, vol. 105, no. 1, pp. 83-88. DOI:10.1038/bjc.2011.216
Russell, S & Tisdale, M 2011, 'Studies on the anti-obesity activity of zinc-a2-glycoprotein in the rat' International Journal of Obesity, vol. 35, no. 5, PMID:20856251, pp. 658-665. DOI:10.1038/ijo.2010.193
Russell, S & Tisdale, M 2011, 'Studies on the antiobesity effect of zinc-a2-glycoprotein in the ob/ob mouse' International Journal of Obesity, vol. 35, no. 3, PMID:20697416, pp. 345-354. DOI:10.1038/ijo.2010.150
Russell, S & Tisdale, M 2010, 'Mechanism of attenuation of skeletal muscle atrophy by zinc-a₂-glycoprotein' Endocrinology, vol. 151, no. 10, pp. 4696-4704. DOI:10.1210/en.2010-0532
Tisdale, MJ 2010, 'Reversing cachexia' Cell, vol. 142, no. 4, pp. 511-512. DOI:10.1016/j.cell.2010.08.004
Tisdale, MJ 2010, 'Are tumoral factors responsible for host tissue wasting in cancer cachexia?' Future Oncology, vol. 6, no. 4, pp. 503-513. DOI:10.2217/fon.10.20
Tisdale, MJ 2010, 'Cancer cachexia' Current Opinion in Gastroenterology, vol. 26, no. 2, pp. 146-151. DOI:10.1097/MOG.0b013e3283347e77
Russell, ST & Tisdale, MJ 2010, 'Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice' Endocrinology, vol. 151, no. 3, pp. 948-957. DOI:10.1210/en.2009-0827
Russell, S, Siren, PMA, Siren, MJ & Tisdale, M 2010, 'The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate' British Journal of Cancer, vol. 102, no. 5, pp. 833–836. DOI: 10.1038/sj.bjc.6605562
Russell, ST, Siren, PMA, Siren, MJ & Tisdale, MJ 2010, 'Mechanism of attenuation of protein loss in murine C₂C₁₂myotubes by d-myo-inositol 1,2,6-triphosphate' Experimental Cell Research, vol. 316, no. 2, pp. 286-295. DOI:10.1016/j.yexcr.2009.08.013
Eley, HL, Russell, ST & Tisdale, MJ 2010, 'Mechanism of activation of dsRNA-dependent protein kinase (PKR) in muscle atrophy' Cellular Signalling, vol. 22, no. 5, pp. 783-790. DOI:10.1016/j.cellsig.2010.01.002
Tisdale, MJ 2010,Adipose tissue cachexia. in T Leff & JG Granneman (eds),Adipose tissue in health and disease.Wiley-VCH, Weinheim (DE), pp. 333-345. DOI:10.1002/9783527629527.ch17
Tisdale, MJ 2009, 'Zinc-a2-glycoprotein in cachexia and obesity' Current Opinion in Supportive and Palliative Care, vol. 3, no. 4, pp. 288-293. DOI:10.1097/SPC.0b013e328331c897
Russell, ST & Tisdale, MJ 2009, 'Mechanism of attenuation by ß-hydroxy-ß-methylbutyrate of muscle protein degradation induced by lipopolysaccharide' Molecular and Cellular Biochemistry, vol. 330, no. 1-2, pp. 171-179. DOI:10.1007/s11010-009-0130-5
Russell, ST, Siren, PMA, Siren, MJ & Tisdale, MJ 2009, 'Attenuation of skeletal muscle atrophy in cancer cachexia by d-myo-inositol 1,2,6-triphosphate' Cancer Chemotherapy and Pharmacology, vol. 64, no. 3, pp. 517-527. DOI:10.1007/s00280-008-0899-z
Tisdale, MJ 2009, 'Mechanisms of Cancer Cachexia' Physiological Reviews, vol. 89, no. 2, pp. 381-410. DOI:10.1152/physrev.00016.2008
Eley, HL, McDonald, PS, Russell, ST & Tisdale, MJ 2009, 'Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition' Cancer Chemotherapy and Pharmacology, vol. 63, no. 4, pp. 651-659. DOI:10.1007/s00280-008-0782-y
Russell, ST, Rajani, S, Dhadda, RS & Tisdale, MJ 2009, 'Mechanism of induction of muscle protein loss by hyperglycaemia' Experimental Cell Research, vol. 315, no. 1, pp. 16-25. DOI:10.1016/j.yexcr.2008.10.002
Eley, HL, Russell, ST & Tisdale, MJ 2008, 'Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by ß-hydroxy-ß-methylbutyrate' American Journal of Physiology, vol. 295, no. 6. DOI:10.1152/ajpendo.90530.2008
Eley, HL, Russell, ST & Tisdale, MJ 2008, 'Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-a and angiotensin II by ß-hydroxy-ß- methylbutyrate' American Journal of Physiology, vol. 295, no. 6. DOI:10.1152/ajpendo.90567.2008
Tisdale, MJ 2008, 'Catabolic mediators of cancer cachexia' Current Opinion in Supportive and Palliative Care, vol. 2, no. 4, pp. 256-261. DOI:10.1097/SPC.0b013e328319d7fa
Eley, HL, Russell, ST & Tisdale, MJ 2008, 'Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate' American Journal of Physiology, vol. 295, no. 6, pp. E1417-E1426. DOI:10.?1152/?ajpendo.?90567.?2008
Eley, HL, Russell, ST & Tisdale, MJ 2008, 'Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate' American Journal of Physiology, vol. 295, no. 6, pp. E1409-E1416. DOI:10.?1152/?ajpendo.?90530.?2008
Khal, J & Tisdale, MJ 2008, 'Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA)' Biochemical and Biophysical Research Communications, vol. 375, no. 2, pp. 238-240. DOI:10.1016/j.bbrc.2008.08.004
Eley, HL, Russell, ST & Tisdale, MJ 2008, 'Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I)' Molecular and Cellular Biochemistry, vol. 313, no. 1-2, pp. 63-69. DOI:10.1007/s11010-008-9742-4
Tisdale, MJ 2008, 'Re: Wieland BM, et al. is there a human homologue to the murine proteolysis - inducing factor?' Clinical Cancer Research, vol. 14, no. 7, pp. 2245. DOI:10.1158/1078-0432.CCR-07-4769
Russell, ST, Eley, HL, Wyke, SM & Tisdale, MJ 2008, 'Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor' Biochemical Journal, vol. 409, no. Part 3, pp. 751-759. DOI:10.1042/BJ20070688
Eley, HL, Skipworth, RJE, Deans, DAC, Fearon, KCH & Tisdale, MJ 2008, 'Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2 alpha may signal skeletal muscle atrophy in weight-losing cancer patients' British Journal of Cancer, vol. 98, no. 2, pp. 443-449. DOI:10.1038/sj.bjc.6604150
Yano, CL, Ventrucci, G, Field, WN, Tisdale, MJ & Gomes-Marcondes, MCC 2008, 'Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes' BMC Cancer, vol. 8, no. 24, pp. 24-. DOI:10.1186/1471-2407-8-24

Professor Michael J. Tisdale

Professor of Cancer Biochemistry

Member of the Pharmacy and Biology Teaching Programmes

Research Theme

Research Centre

Profile

Qualifications

Career History

Teaching Activity

Research Interests

Research Funding

Recent Publications